Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
APUSthis companyApimeds Pharmaceuticals US, Inc	$2.69	-2.98×	0.12×	0×	-4.2×	-321.0%	0.0%	0.0%	0.0%	-3.9%	-7.4%	-50.3%	0.05×	-1.07×	-42.09×	1.31×	0.0%	1	-2.08	2	C+
ANTXAN2 Therapeutics, Inc.	$4.04	-0.98×	0.65×	0×	-0.41×	-86.4%	0.0%	0.0%	0.0%	-66.3%	-71.6%	-86.6%	0×	0.57×	0×	6.87×	0.0%	1	12.25	1	C-
IGCIGC Pharma, Inc.	$0.20	-3.64×	4.08×	21.08×	-3.96×	-225.3%	29.7%	-860.3%	-552.1%	-107.0%	-144.8%	-24.4%	0.15×	-0.11×	0×	0.4×	0.0%	1	-18.6	1	C-
MIRAMIRA Pharmaceuticals, Inc.	$0.59	-1.12×	3.44×	0×	-2.82×	-51.0%	0.0%	0.0%	0.0%	-100.5%	-101.0%	-13.0%	0×	0.61×	0×	15.75×	0.0%	2	320.98	1	C-
MLSSMilestone Scientific Inc.	$0.31	-3.9×	7.97×	2.5×	-4.05×	-405.4%	70.5%	-63.5%	-63.8%	-203.4%	-148.6%	-13.1%	0.36×	0.02×	-222.53×	1.81×	0.0%	3	-19.32	1	C-
MYOMyomo, Inc.	$1.27	-2.46×	3.34×	0.93×	-3.56×	-1616.4%	65.7%	-35.2%	-38.1%	-136.6%	-46.8%	-42.7%	1.7×	-0.43×	-15.52×	3.3×	0.0%	2	-3.46	2	C
Peer median	—	-2.46×	3.44×	0.93×	-3.56×	-225.3%	29.7%	-35.2%	-38.1%	-107.0%	-101.0%	-24.4%	0.15×	0.02×	0×	3.3×	0.0%	2	-3.46	1	—